Stella Pharma Corporation provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of ¥192 million, operating loss of ¥948 million, loss of ¥936 million, basic loss per share of ¥32.64.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
350 JPY | +1.74% | +15.89% | +22.81% |
02-13 | Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024 | CI |
2023 | Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+22.81% | 69.38M | |
+33.85% | 709B | |
+30.60% | 595B | |
-2.42% | 367B | |
+20.41% | 334B | |
+5.09% | 289B | |
+14.11% | 239B | |
+9.01% | 211B | |
-3.80% | 203B | |
+8.30% | 171B |
- Stock Market
- Equities
- 4888 Stock
- News Stella Pharma Corporation
- Stella Pharma Corporation Provides Earnings Guidance for the Year Ending March 31, 2023